β2 Microglobulin Antibody [D17A9]

Catalog No.: F4890

Application: Reactivity: Mouse, Rat, Human

Lane 1: Hela, Lane 2: Hela (KO B2M), Lane 3: Mouse kidney, Lane 4: Rat kidney

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:5000 IP1:20-1:40 IF1:100-1:250 FCM1:20-1:60

Application
WB, IP, IF, FCM

Source
Rabbit Monoclonal Antibody

Reactivity
Mouse, Rat, Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
14 kDa 14 kDa, 12 kDa
^*なぜ予測分子量と実際の分子量が異なるのか？下記の原因により、実際の分子量が予測と異なる：タンパク質の翻訳後修飾（リン酸化/糖鎖付加），スプライシングバリアント，イソフォーム，相対的な電荷，ポリマー。

Datasheet & SDS

生物学的記述

Specificity
β2 Microglobulin Antibody [D17A9] detects endogenous levels of total β2 Microglobulin protein.

Clone
D17A9

Synonym(s)
CDABP0092, HDCMA22P, B2M, Beta-2-microglobulin

Background
Beta‑2‑microglobulin (β2M; B2M) is a small, invariant subunit of the class I major histocompatibility complex (MHC I) that is expressed on the surface of nearly all nucleated cells and is required for the proper folding, stability, and cell‑surface expression of MHC I molecules. Within the endoplasmic reticulum, β2M noncovalently associates with the polymorphic MHC I heavy chain and undergoes an assembly process that allows loading of intracellularly derived peptides via the peptide‑loading complex, including TAP and tapasin; this β2M‑containing MHC I‑peptide complex is then transported to the plasma membrane, where it is surveyed by CD8⁺ T cells to detect infected or malignant cells. β2M also participates in the neonatal Fc receptor (FcRn) pathway, where it stabilizes and extends the half‑life of immunoglobulin‑G by enabling pH‑dependent binding and recycling of IgG, thereby linking β2M to humoral immunity and albumin‑handling physiology. β2M is filtered by the glomerulus and catabolized by proximal tubules, so serum and urinary β2M levels rise in chronic kidney disease, multiple myeloma, and some lymphoproliferative disorders, and serum β2M is used as a prognostic staging parameter in myeloma and as a marker of disease burden and immune‑activation status in other malignancies. Excess β2M can deposit in joint and connective tissues, and genetic or acquired defects in β2M or MHC I trafficking can impair immune surveillance and alter responses to infection and cancer in amyloidogenic conditions such as dialysis‑related amyloidosis.

Background

Beta‑2‑microglobulin (β2M; B2M) is a small, invariant subunit of the class I major histocompatibility complex (MHC I) that is expressed on the surface of nearly all nucleated cells and is required for the proper folding, stability, and cell‑surface expression of MHC I molecules. Within the endoplasmic reticulum, β2M noncovalently associates with the polymorphic MHC I heavy chain and undergoes an assembly process that allows loading of intracellularly derived peptides via the peptide‑loading complex, including TAP and tapasin; this β2M‑containing MHC I‑peptide complex is then transported to the plasma membrane, where it is surveyed by CD8⁺ T cells to detect infected or malignant cells. β2M also participates in the neonatal Fc receptor (FcRn) pathway, where it stabilizes and extends the half‑life of immunoglobulin‑G by enabling pH‑dependent binding and recycling of IgG, thereby linking β2M to humoral immunity and albumin‑handling physiology. β2M is filtered by the glomerulus and catabolized by proximal tubules, so serum and urinary β2M levels rise in chronic kidney disease, multiple myeloma, and some lymphoproliferative disorders, and serum β2M is used as a prognostic staging parameter in myeloma and as a marker of disease burden and immune‑activation status in other malignancies. Excess β2M can deposit in joint and connective tissues, and genetic or acquired defects in β2M or MHC I trafficking can impair immune surveillance and alter responses to infection and cancer in amyloidogenic conditions such as dialysis‑related amyloidosis.

References
[1] Hyafil F, et al. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5834-8. [2] Argyropoulos CP, et al. Front Med (Lausanne). 2017 Jun 15;4:73.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%